Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

NCT02143973 is registered in ClinicalTrials.gov with Trevi Therapeutics as lead sponsor.

NCT NCT02143973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02143973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Lead sponsor
Trevi Therapeutics
Phase
Phase 2/3
Overall status
Completed
Start date
September 30, 2014
Completion date
January 31, 2016
Enrollment
167 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

pruritus, uremic pruritus